PureTech Health plc (NASDAQ:PRTC - Get Free Report) shares gapped up before the market opened on Friday . The stock had previously closed at $21.03, but opened at $23.67. PureTech Health shares last traded at $23.69, with a volume of 623 shares traded.
Analyst Ratings Changes
Several brokerages have issued reports on PRTC. Leerink Partnrs upgraded shares of PureTech Health to a "strong-buy" rating in a research note on Monday, September 9th. Leerink Partners began coverage on PureTech Health in a report on Monday, September 9th. They issued an "outperform" rating and a $45.00 price objective for the company.
Get Our Latest Stock Report on PRTC
PureTech Health Stock Performance
The company has a 50-day simple moving average of $21.00 and a two-hundred day simple moving average of $22.91.
Institutional Inflows and Outflows
An institutional investor recently bought a new stake in PureTech Health stock. Birch Hill Investment Advisors LLC acquired a new stake in PureTech Health plc (NASDAQ:PRTC - Free Report) in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 302,000 shares of the company's stock, valued at approximately $7,550,000. Birch Hill Investment Advisors LLC owned 1.26% of PureTech Health at the end of the most recent reporting period. Institutional investors and hedge funds own 0.04% of the company's stock.
About PureTech Health
(
Get Free Report)
PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies.
Read More
Before you consider PureTech Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and PureTech Health wasn't on the list.
While PureTech Health currently has a "Strong Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
